Treatment of Thyrotoxic Periodic Paralysis

Acute Management

• The European Society of Cardiology recommends beta-blockers, particularly propranolol, as an alternative or adjunctive first-line therapy for acute management of thyrotoxic periodic paralysis, due to the role of hyperadrenergic activity in pathogenesis 1, 2, 3, 4, 5

Definitive Management

• The American College of Cardiology and the European Society of Cardiology recommend beta-blockers as Class I therapy for rate control in patients with atrial fibrillation complicating thyrotoxicosis, and calcium channel antagonists as recommended alternatives when beta-blockers cannot be used 1, 2, 3, 4, 5
• The American College of Cardiology and the European Heart Journal suggest that achieving and maintaining a euthyroid state is the only way to prevent future attacks of thyrotoxic periodic paralysis, and that beta-blockers should be continued during the transition to euthyroid status 1, 2, 3, 4, 5

Common Pitfalls to Avoid

• The European Heart Journal and the American College of Cardiology warn that antiarrhythmic drugs and electrical cardioversion are generally unsuccessful while thyrotoxicosis persists, and that efforts should focus on rate control and achieving euthyroid status rather than rhythm control 1, 2, 3, 4, 5